Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 57 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Mupirocin Clear all
Completed Not applicable Interventional Results available

Checklist to Prevent MRSA Surgical Site Infections

NCT02216227
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Mupirocin, Chlorhexidine gluconate, Cefazolin, Vancomycin, Nasal Povidone Iodine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
23,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Preventing Staphylococcal (Staph) Infection

NCT00108160
View directory record Official record
Conditions
Staphylococcal Infections
Interventions
Mupirocin Ointment [Treatment], Polyethylene Glycol Ointment [Placebo]
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 3 Interventional Results available

To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Secondarily Infected Traumatic Skin Lesions

NCT04155203
View directory record Official record
Conditions
Secondarily Infected Traumatic Skin Lesions
Interventions
Mupirocin Calcium, Vehicle
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
18 Months and older
Enrollment
657 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
West Palm Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Bacterial Decolonization Within Dyads

NCT06541145
View directory record Official record
Conditions
Bacterial Colonization
Interventions
Mupirocin, Chlorhexidine baths
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Female only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Stop Community MRSA Colonization Among Patients

NCT02029872
View directory record Official record
Conditions
MRSA
Interventions
Chlorhexidine gluconate soap, Chlorhexidine gluconate oral rinse, Mupirocin calcium 2 % ointment
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
6 Months and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 20, 2018 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

STaph Aureus Resistance-Treat Early and Repeat (STAR-TER)

NCT03489629
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Trimethoprim Sulfamethoxazole (TMP/SMX), Minocycline, Mupirocin, Chlorhexidine Gluconate, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
2 Years to 45 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Indianapolis, Indiana • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Epidemiology and Prevention of Methicillin Resistant Staphylococcus Aureus (MRSA) Transmission in the Community

NCT00966446
View directory record Official record
Conditions
MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Unsupervised Decolonization, Supervised Decolonization
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
6 Months and older
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
4
States / cities
Hershey, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 17, 2026, 4:48 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

NCT06805994
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Microbial Colonization, Pediatric Infection, S. Aureus Colonization, Microbial Transplant
Interventions
Nasal Microbiota Transplant (NMT), Placebo
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
0 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Retapamulin for Reducing MRSA Nasal Carriage

NCT01461668
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus
Interventions
Retapamulin, Placebo
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2018 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Cluster Randomized Trial of Hospitals to Assess Impact of Targeted Versus Universal Strategies to Reduce Methicillin-resistant Staphylococcus Aureus (MRSA) in Intensive Care Units (ICUs)

NCT00980980
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Chlorhexidine bath and nasal mupirocin
Drug
Lead sponsor
Harvard Pilgrim Health Care
Other
Eligibility
13 Years and older
Enrollment
74,256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
42
States / cities
Anchorage, Alaska • Thousand Oaks, California • Aurora, Colorado + 32 more
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 17, 2026, 4:48 PM EDT
Recruiting Phase 4 Interventional

Decolonization to Reduce After-Surgery Events of Surgical Site Infection

NCT05586776
View directory record Official record
Conditions
Surgical Site Infection
Interventions
4% Chlorhexidine Gluconate, 2% Mupirocin, Soap Without Antiseptic Properties (Placebo), Placebo Nasal Ointment
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
4
States / cities
Newport Beach, California • Orange, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional

Staph Intervention for Effective Local Defense

NCT06210594
View directory record Official record
Conditions
Staphylococcus Aureus Infection
Interventions
Mupirocin + Nozin + chlorhexidine gluconate, Education + Household supplies
Combination Product · Behavioral
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Whiteriver, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Effect of Mupirocin Dressings Versus Island Dressings on Surgical Site Infections in Elective Colorectal Surgery

NCT02619773
View directory record Official record
Conditions
Surgical Site Infections
Interventions
mupirocin ointment
Procedure
Lead sponsor
Gundersen Lutheran Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 17, 2026, 4:48 PM EDT
Recruiting No phase listed Observational

Effectiveness of Screening and Decolonization of S. Aureus to Prevent S. Aureus Surgical Site Infections in Surgery Outpatients

NCT06378359
View directory record Official record
Conditions
Staphylococcus Aureus Colonization, Surgical Site Infections, Healthcare Associated Infections
Interventions
Screening and decolonization for SA carriers with the 3 drug bundle, No screening for SA, no screening, Nasal povidone-iodine on surgery day plus 2 CHG pre-op showers without screening., Nasal alcohol gel on surgery day plus 2 CHG pre-op showers without screening
Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

Staph Household Intervention for Eradication (SHINE)

NCT02572791
View directory record Official record
Conditions
Skin and Subcutaneous Tissue Bacterial Infections, Staphylococcus Aureus, MRSA - Methicillin Resistant Staphylococcus Aureus Infection
Interventions
Chlorhexidine, Mupirocin, Household cleaning
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Up to 18 Years
Enrollment
835 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional Results available

Staphylococcus Aureus Decolonization Study

NCT00731783
View directory record Official record
Conditions
Staphylococcal Skin Infections, Abscesses, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% Mupirocin Ointment, 4% Chlorhexidine liquid soap, Hygiene protocol
Drug · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
6 Months to 21 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Results available

The Use of Antibiotic Sinonasal Rinse After Sinus Surgery

NCT02218307
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
Mupirocin, Placebo
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Attempt to Reduce Community-Acquired Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection in Soldiers

NCT00289588
View directory record Official record
Conditions
Community-Acquired MRSA Infections, Abscesses, Cellulitis, Folliculitis
Interventions
Mupirocin (drug)
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
17 Years to 60 Years
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2006 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Not applicable Interventional

Prophylaxis Prior to Cataract Surgery Conjunctival Flora and Optimal Ocular Sterilization Technique Prior to Cataract Surgery

NCT00406913
View directory record Official record
Conditions
Endophthalmitis, Cataract Surgery, Prophylaxis
Interventions
mupirocin ointment, SOC sterilization
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 17, 2026, 4:48 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

S. Aureus Screening and Decolonization

NCT02182115
View directory record Official record
Conditions
Wound Infection Due to Staphylococcus Aureus, MRSA Infection of Postoperative Wound
Interventions
antiseptic bundle, standard of care
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 17, 2026, 4:48 PM EDT
Withdrawn Phase 2 Interventional

Topical Steroids & Bacterial Decolonization for Radiation Dermatitis

NCT05505214
View directory record Official record
Conditions
Radiation Dermatitis
Interventions
Bacterial decolonization, Mometasone furoate 0.1% cream, Bacterial decolonization and Mometasone furoate 0.1% cream
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2023 · Synced Oct 17, 2026, 4:48 PM EDT
Terminated Phase 4 Interventional Results available

MRSA Eradication and Decolonization in Children

NCT02127658
View directory record Official record
Conditions
MRSA
Interventions
Hygiene education, Sodium Hypochlorite, Mupirocin ointment
Other · Drug
Lead sponsor
Indiana University
Other
Eligibility
3 Months to 18 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 25, 2024 · Synced Oct 17, 2026, 4:48 PM EDT
Terminated Phase 2 Interventional Results available

Early Methicillin-resistant Staphylococcus Aureus (MRSA) Therapy in Cystic Fibrosis (CF)

NCT01349192
View directory record Official record
Conditions
Cystic Fibrosis, Methicillin-resistant Staphylococcus Aureus
Interventions
Rifampin, Trimethoprim/Sulfamethoxazole, Minocycline, Mupirocin, chlorhexidine gluconate oral rinse, 2% Chlorhexidine solution wipes, Environmental Decontamination
Drug · Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 45 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
13
States / cities
Birmingham, Alabama • Aurora, Colorado • Gainesville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated May 15, 2017 · Synced Oct 17, 2026, 4:48 PM EDT